Brokers Offer Predictions for Imunon, Inc.’s FY2028 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNN) – Research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of Imunon in a report released on Monday, April 1st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.32) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Imunon’s current full-year earnings is ($1.95) per share.

Imunon Trading Up 17.7 %

Shares of Imunon stock opened at $1.93 on Tuesday. The company’s fifty day simple moving average is $0.79 and its two-hundred day simple moving average is $0.86. The company has a market cap of $18.14 million, a P/E ratio of -0.89 and a beta of 2.02. Imunon has a 12-month low of $0.48 and a 12-month high of $2.00.

Institutional Trading of Imunon

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Imunon by 20.1% during the 2nd quarter. Renaissance Technologies LLC now owns 74,011 shares of the company’s stock valued at $95,000 after buying an additional 12,400 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Imunon during the 1st quarter valued at $83,000. Finally, Geode Capital Management LLC bought a new stake in shares of Imunon during the 1st quarter valued at $62,000. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.